Yates Josephine, Van Allen Eliezer M
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Institute for Machine Learning, Department of Computer Science, ETH Zürich, Zurich, Switzerland; ETH AI Center, ETH Zurich, Zurich, Switzerland; Swiss Institute for Bioinformatics (SIB), Lausanne, Switzerland.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA; Division of Medical Sciences, Harvard University, Boston, MA, USA; Parker Institute for Cancer Immunotherapy, Dana-Farber Cancer Institute, Boston, MA, USA.
Cancer Cell. 2025 Apr 14;43(4):708-727. doi: 10.1016/j.ccell.2025.03.018.
Artificial intelligence (AI) is increasingly being utilized in cancer research as a computational strategy for analyzing multiomics datasets. Advances in single-cell and spatial profiling technologies have contributed significantly to our understanding of tumor biology, and AI methodologies are now being applied to accelerate translational efforts, including target discovery, biomarker identification, patient stratification, and therapeutic response prediction. Despite these advancements, the integration of AI into clinical workflows remains limited, presenting both challenges and opportunities. This review discusses AI applications in multiomics analysis and translational oncology, emphasizing their role in advancing biological discoveries and informing clinical decision-making. Key areas of focus include cellular heterogeneity, tumor microenvironment interactions, and AI-aided diagnostics. Challenges such as reproducibility, interpretability of AI models, and clinical integration are explored, with attention to strategies for addressing these hurdles. Together, these developments underscore the potential of AI and multiomics to enhance precision oncology and contribute to advancements in cancer care.
人工智能(AI)作为一种用于分析多组学数据集的计算策略,在癌症研究中越来越多地得到应用。单细胞和空间分析技术的进步极大地促进了我们对肿瘤生物学的理解,目前人工智能方法正被用于加速转化研究工作,包括靶点发现、生物标志物识别、患者分层和治疗反应预测。尽管取得了这些进展,但人工智能在临床工作流程中的整合仍然有限,既带来了挑战,也带来了机遇。本综述讨论了人工智能在多组学分析和转化肿瘤学中的应用,强调了它们在推进生物学发现和为临床决策提供信息方面的作用。重点关注的关键领域包括细胞异质性、肿瘤微环境相互作用和人工智能辅助诊断。探讨了诸如可重复性、人工智能模型的可解释性以及临床整合等挑战,并关注解决这些障碍的策略。这些进展共同强调了人工智能和多组学在提高精准肿瘤学水平以及推动癌症护理进步方面的潜力。